SMMT 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼
SMMT 近期報酬表現
-1.55%
Summit therapeutics inc
4.57%
同產業平均
0.12%
S&P500
與 SMMT 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
PHVS | Pharvaris nv | 2 分 | 1 分 | 4 分 | 3 分 | 1 分 | |
NBTX | Nanobiotix sa - adr | - | 3 分 | 3 分 | 1 分 | 1 分 | |
ERNA | Eterna therapeutics inc | 2 分 | 5 分 | 3 分 | - | 1 分 | |
KTRA | Kintara therapeutics inc | 1 分 | 3 分 | 2 分 | 1 分 | 1 分 | |
MLYS | Mineralys therapeutics inc | - | 4 分 | 4 分 | 2 分 | 1 分 |
- PHVS Pharvaris nv價值 2 分趨勢 1 分波段 4 分籌碼 3 分股利 1 分查看更多
SMMT 公司資訊
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.